The last annual report (July to Dec 2017) reported on four divisions:
1 - Medical products and devices
2 - Bio implant operations
3 - Regenerative medicine R&D
4- Immunotherapies R&D
It showed that immunotherapies had zero revenue and a loss of $852,422 for the six months from July to Dec 2017.
Immunotherapy assets, as you say, were $4.79. Also, as you say, most of that would be IP. I don't know how much cash is on its books and when AHZ last topped up their share of the costs.
But if they lose say $852k * 2 = $1.7 million per annum, AHZ's pro-rata share of these costs would be 72.8% of these costs.
What I wonder is how much they tipped in (if anything) for these costs in the last few quarters. Surely there isn't much cash in the immunotherapy account to have not required top ups from AHZ for that long.
- Forums
- ASX - By Stock
- AVR
- Twiggy can this...
Twiggy can this..., page-21
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.50 |
Change
0.100(0.65%) |
Mkt cap ! $319.3M |
Open | High | Low | Value | Volume |
$15.15 | $15.50 | $15.00 | $108.6K | 7.185K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 341 | $15.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.50 | 371 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 341 | 15.000 |
1 | 1000 | 14.990 |
1 | 1000 | 14.900 |
1 | 1000 | 14.850 |
2 | 262 | 14.800 |
Price($) | Vol. | No. |
---|---|---|
15.500 | 371 | 1 |
15.660 | 1925 | 2 |
15.850 | 554 | 1 |
15.950 | 848 | 2 |
16.030 | 999 | 1 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online